Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-08

Study Completion Date

2025-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Introduction: Transthyretin cardiac amyloidosis (ATTR) is an important cause of heart failure. Cardiac planar radionuclide imaging using 99mTc-labeled bone seeking radiopharmaceuticals is used as a noninvasive diagnostic criterion in patients without detectable monoclonal protein. The visual assessment remains the main noninvasive criterion for the diagnosis. Medical therapy using tafamidis meglumine that binds to transthyretin and prevents amyloidogenesis, recently demonstrated a reduction in all-cause mortality and cardiovascular-related hospitalizations. As a consequence, there is a need for quantitative approaches that would be useful for diagnosis and prognosis assessment but also for the evaluation of patient therapeutic response.

Materials and methods: The investigators aim to include 35 patients with a suspected diagnosis of cardiac ATTR amyloidosis in whom a cardiac planar radionuclide imaging using 99mTc-labeled bone seeking radiopharmaceuticals is planned as part of routine noninvasive diagnosis work-up. Using a test-retest approach, the aim is to compare a quantitative method vs. conventional semi-quantitative approaches for the assessment of cardiac uptake of bone radiopharmaceuticals using new 3D CZT-based SPECT-CT cameras in patients with suspected cardiac ATTR amyloidosis. The investigators estimated that 20 patients will have a diagnosis of cardiac ATTR amyloidosis. In the latter patients, the aim is to evaluate the impact of 6-month therapy using tafamidis on quantitative and semi-quantitative assessment of cardiac uptake of bone radiopharmaceuticals Perspectives: This new non invasive imaging techniques for the quantitative assessment of the amyloid burden in patients with cardiac ATTR amyloidosis may help identify the responders and the patients who should benefit from dose intensification.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy

NCT04849754

Cardiac Amyloidosis

RECRUITING NA

Assessment of 18F-Florbetaben Whole-body PET for the Detection of Cardiac and Extracardiac Sites of Amyloid Deposits

NCT03616496

Cardiac Amyloidosis

COMPLETED NA

ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy

NCT04513600

Transthyretin Amyloidosis

UNKNOWN

Quantitative-imaging in Cardiac Transthyretin Amyloidosis

NCT05776212

ATTR-CM

RECRUITING

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

NCT06073574

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyloidosis Transthyretin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No cardiac ATTR amyloidosis

Cardiac echocardiography at baseline and whole-body \& CZT bone tracer imaging (SPECT).

day 3 - day 10 : second whole-body \& CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging Perugini 0 : no cardiac TTR amyloidosis No further follow-up.

Group Type OTHER

Whole-body & CZT bone tracer imaging (SPECT)

Intervention Type DIAGNOSTIC_TEST

Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras

Cardiac ATTR amyloidosis, no treatment with tafamidis planned

Cardiac echocardiography at baseline and whole-body \& CZT bone tracer imaging (SPECT).

day 3 - day 10 : second whole-body \& CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis but no treament with tafamidis planned.

Cardiac echocardiography at 3 months and whole-body \& CZT bone tracer SPECT and cardiac echocardiography at 6 months

Group Type OTHER

Whole-body & CZT bone tracer imaging (SPECT)

Intervention Type DIAGNOSTIC_TEST

Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras

Cardiac ATTR amyloidosis, treatment with tafamidis planned

Cardiac echocardiography at baseline and whole-body \& CZT bone tracer imaging (SPECT).

day 3 - day 10 : second whole-body \& CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis. Start of the treament with tafamidis.

Cardiac echocardiography at 3 months and whole-body \& CZT bone tracer SPECT and cardiac echocardiography at 6 months

Group Type OTHER

Whole-body & CZT bone tracer imaging (SPECT)

Intervention Type DIAGNOSTIC_TEST

Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Whole-body & CZT bone tracer imaging (SPECT)

Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Medical history of Heart Failure (HF) with at least 1 prior hospitalization for HF or clinical evidence of HF (without hospitalization) manifested by signs or symptoms of volume overload or elevated intracardiac pressures that required/requires treatment with a diuretic for improvement, and an increase of BNP \>200 pg/mL and/or NT-proBNP \>500 pg/mL
* Suspected cardiac ATTR amyloidosis
* Evidence of cardiac involvement by echocardiography with an end-diastolic interventricular septal wall thickness \> 12 mm
* Patient signed consent
* Contraception method

Exclusion Criteria

* New York Heart Association (NYHA) functional class IV despite diuretic treatment
* Life expectancy \<6 month due to the severity of cardiac amyloidosis and/or comorbidities
* Aortic valve surgical or percutaneous replacement within 30 days or planned within months
* Presence of primary (light chain) amyloidosis
* Contraindication to tafamidis
* Pregnancy and breast feeding ; pregnancy test in women of reproductive age irrespective of contraception method)
* Adults with protective measures

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No